Exactech Inc. (NASDAQ:EXAC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The firm presently has a $31.00 price objective on the stock. Zacks Investment Research’s price objective suggests a potential upside of 13.51% from the stock’s current price.
According to Zacks, “Exactech, Inc. develops, manufactures, markets and distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally.
